Literature DB >> 8280708

A genetic approach to idiotypic vaccination.

R E Hawkins1, G Winter, T J Hamblin, F K Stevenson, S J Russell.   

Abstract

Treatment of cancer with vaccines is an attractive prospect, but few tumours express suitable target antigens. With B-cell lymphomas, the idiotypic immunoglobulin (Ig) of the malignant B-cell should provide a suitable target but this requires a vaccine to be created for each patient. We propose a strategy for making such vaccines: first to clone the V genes of the idiotypic Ig, and second to inject the patient with the cloned DNA (genetic immunisation) in order to elicit an immune response against the encoded Ig. We have previously shown that the V genes of the idiotypic Ig can be identified from human lymph node biopsies by polymerase chain reaction amplification, cloning, and sequencing. In this report, we show that anti-idiotypic antibodies can be elicited by direct injection of an expression vector that encodes the V genes of murine antibodies (the V genes of B1.8, a murine hybridoma or of BCL1, a murine lymphoma line). This finding suggests a simple approach to the preparation of idiotypic vaccines for patients with B-cell lymphoma, which also circumvents the need for adjuvants.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8280708     DOI: 10.1097/00002371-199311000-00004

Source DB:  PubMed          Journal:  J Immunother Emphasis Tumor Immunol        ISSN: 1067-5582


  9 in total

Review 1.  Vaccination strategies for lymphomas.

Authors:  Mohammed M Dar; Larry W Kwak
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

Review 2.  DNA vaccines: developing new strategies to enhance immune responses.

Authors:  Shaheed A Abdulhaqq; David B Weiner
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 3.  Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials.

Authors:  Hyun Jun Park; Sattva S Neelapu
Journal:  Br J Haematol       Date:  2008-04-13       Impact factor: 6.998

Review 4.  Vectors for cancer gene therapy.

Authors:  J Zhang; S J Russell
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

Review 5.  Immunotherapy III: Combinatorial molecular immunotherapy--a synthesis and suggestions.

Authors:  R G Vile; H Chong
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

Review 6.  Genes, dreams, and cancer.

Authors:  K Sikora
Journal:  BMJ       Date:  1994-05-07

Review 7.  Therapeutic vaccine for lymphoma.

Authors:  Seung-Tae Lee; Sattva S Neelapu; Larry W Kwak
Journal:  Yonsei Med J       Date:  2007-02-28       Impact factor: 2.759

8.  Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol.

Authors:  Sheeba K Thomas; Soung-Chul Cha; D Lynne Smith; Kun Hwa Kim; Sapna R Parshottam; Sheetal Rao; Michael Popescu; Vincent Y Lee; Sattva S Neelapu; Larry W Kwak
Journal:  BMC Cancer       Date:  2018-02-13       Impact factor: 4.430

9.  Targeted DNA vaccines for enhanced induction of idiotype-specific B and T cells.

Authors:  Agnete B Fredriksen; Inger Sandlie; Bjarne Bogen
Journal:  Front Oncol       Date:  2012-10-30       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.